Introduction
============

Classical swine fever (CSF) is a major threat to commercial pig production worldwide ([@B24]). This multi-systemic disease can affect both domestic pigs and wild boar such that outbreaks among wild boar can significantly impact commercial pig farms. CSF outbreaks among wild boars present a constant threat of introduction into domestic pigs. In Germany during the 1990's, approximately two thirds of primary outbreaks among domestic pigs were attributed to direct or indirect contact with CSF infected wild boar ([@B29]).

Generally, control of wildlife reservoirs is a significant challenge ([@B21]; [@B32]). To combat infectious diseases, vaccination is often used to decrease the proportion of susceptible animals in a population below a threshold needed for disease maintenance among that population ([@B68]; [@B13]).

Different vaccination approaches for wild boar have been developed and tested, some of them directly under field conditions (e.g., lyophilized vaccines in Russia), others under experimental conditions ([@B41]). Under experimental conditions, live attenuated vaccines showed high efficacy and complete safety upon oral immunization of individual animals ([@B41]). To deliver the vaccines on a larger scale, oral bait formulations were subsequently developed and tested by [@B41] during the 1990's. These baits were suitable for oral mass vaccination (OMV) and in the following years the approach was considered as a satisfactory option for improving CSF virus (CSFV) control in wild boar in Western Europe ([@B25]; [@B83]; [@B66]).

However, upon implementation of large scale oral CSF vaccination, it was discovered that the vaccination process and design need further improvement and was subsequently revisited. As a consequence, adaptations were introduced in all areas of CSF control in wild boar including the baiting strategy, population management, and surveillance design ([@B65]). This review addresses and summarizes multiple aspects of oral vaccination of wild boar including its successes and failures, its drawbacks and advantages.

Vaccination Tools
=================

Vaccines
--------

Several CSFV vaccines are available and have been used successfully to control the disease in multiple countries worldwide ([@B82]; [@B33]; [@B17]; [@B56]). The most widely used vaccines are conventional live attenuated vaccines including the well-known lapinised "Chinese" C-strain or its derivatives, and the Thiverval strain. These vaccines have shown outstanding efficacy and safety, but do not allow serological differentiation of infected animals from vaccinated ones; for this reason, vaccinated animals are subject to trade restrictions. To overcome these limitations, marker vaccines have been developed based on different vector platforms and expression systems (for review see [@B12]; [@B23]; [@B15]). These approaches allow differentiation for field detection of virus infection versus vaccination (DIVA; [@B82]; [@B53]).

### Live Attenuated Vaccines

These traditional live attenuated vaccines have been used worldwide in eradication campaigns both intramuscularly (IM) in domestic pigs and in oral bait formulations in wild boar ([@B40]). IM application of these vaccines confers protection a few days after immunization ([@B82]), before neutralizing antibodies are detected. Antibody detection is typically possible within 2 weeks after vaccination ([@B40]; [@B80]). Upon oral immunization, protection is usually conferred within 2 weeks or less ([@B40]; [@B14]; [@B62]), depending on the virulence the pathogenic strain the individual is exposed to. Duration of immunity is at least 6--10 months regardless of the route of administration (intramuscular or oral; [@B40]). Indications exist that immunity might be even life-long. In the European Union (EU), oral vaccination of wild boar has proven to be very effective for the eradication of the virus ([@B25]). The major drawback of live vaccines is that it is impossible to differentiate antibodies induced by field virus infections from antibodies induced by vaccination.

### Marker Vaccines

Baculovirus-expressed E2 recombinant protein subunit vaccines were the first generation of non-replicative marker vaccines for CSF. The efficacy of these two available E2 sub unit vaccines was extensively studied and was determined to be lower than the efficacy of classic C-strain vaccines ([@B79]). Vaccination could not prevent the "carrier sow syndrome" and subsequently the late onset of CSF ([@B22]). An additional drawback of this vaccine is that it cannot be used for oral vaccination in baits. In recent years, new approaches have been used to develop marker vaccines that allow a DIVA principle while having the advantages of live vaccines ([@B12]; [@B15]). Two promising candidates, *pestivirus* chimera "CP7_E2alf" and flc11, were then compared within an EU-funded research project to decide which would be followed up for licensing. Based on the comparative trial and pre-existing data on safety and efficacy, "CP7_E2alf" was chosen for further assessment and marketing ([@B14]).

Regarding the BVDV/CSFV chimera "CP7_E2alf," which carries the CSFV E2 and a BVDV backbone ([@B61]), immunization and challenge trials showed that after a single intramuscular or oral vaccination, the antibody titers were stable for a minimum of 6 months and full protection from lethal challenge infection was observed. In follow-up experiments, this vaccine proved to be safe and efficacious against challenge with CSFV strains of different genotypes and virulence. The vaccine preparation for intra-muscular use has been recently registered in the EU (Suvaxyn CSF Marker, Zoetis), and there is supportive data showing potential for oral vaccination development.

Diagnostic Tools
----------------

For the diagnosis of CSF in wild boar and monitoring following oral vaccination, all methods used for domestic pigs may be used ([@B17]). These techniques include both direct (virus isolation, antigen detection, genome detection) and indirect (antibody) test systems. The commercial E2-ELISA displays a sensitivity that is in general quite similar to the virus neutralization test (VNT). The specificity is usually high, between 98 and \>99.5%. However, cross-reactions may occur with ruminant pestiviruses, especially BDV. Moreover, poor quality of samples derived from wild boar can lead to false positive and negative reactions, especially in ELISA ([@B25]). In recent years, a combination of commercial E2 antibody ELISAs and CSFV specific real-time RT-PCRs has been used to monitor wild boar populations. As CSFV does not present different serotypes, no problems in detecting antibodies against different strains are anticipated (for testing different genotypes see [@B75]). Suitable sample matrices are blood or serum, different organs and even swab samples ([@B5]; [@B59]). Virus isolation in susceptible cell cultures and neutralization tests have been employed as confirmatory assays for CSFV and CSFV specific neutralizing antibodies, respectively. For C-strain vaccination scenarios, sampling and testing strategies have been developed that allow targeted testing ([@B39]). Live attenuated vaccine strains such as the C-strain or CP7_E2alf show a very limited replication even in the target host ([@B48]). However, highly sensitive detection techniques such as real-time RT-PCR can lead to vaccine virus detection in blood and organs from wild boars that have received oral vaccination ([@B16]). To rapidly differentiate these detections from field virus infection (genetic DIVA), specific real-time RT-PCR systems have been developed for different C-strain variants and marker vaccine CP7_E2alf ([@B54]; [@B36]; [@B53]). While traditional live attenuated vaccines do not allow a serological DIVA concept, CP7_E2alf has a marker system that is based on the detection of CSFV Erns antibodies. Animals vaccinated with CP7_E2alf will carry CSFV E2 but not CSFV Erns antibodies while field virus infected animals will also show CSFV Erns responses. At present, one Erns ELISA is commercially available (PrioCHECK CSFV Erns, Thermofisher) and additional approaches are currently under development based on either ELISA or Luminex technology (e.g., [@B1]; [@B84]).

Baits
-----

For a feasible oral immunization scheme, a suitable delivery vehicle in the form of bait is needed. Such baits need to fulfill a wide range of requirements. The most obvious requirement is the acceptance of the bait by the target species. Bait detectability (odor, color), palatability (taste), and uptake must all be considered. Wild boars are omnivores and consume a wide range of foods, but can have very clear preferences for certain food items such as acorns ([@B18]; [@B10]). During initial bait studies with wild boars kept in enclosures, no clear preference were observed between different aromas tested (e.g., apple, corn, almond, hazelnut, truﬄe, potatoes). This was also confirmed during subsequent field studies with free-ranging wild boars ([@B76]). The animals tend to prefer baits containing plant-derived compounds, especially corn meal, over animal-derived compounds ([@B76]). Based on these studies, the present commercial bait matrix that accompanies the Riemser Schweinepestoralvakzine (IDT Biologika, former Riemser Arzneimittel) consists of corn meal, paraffin wax, milk powder, aroma (almond), and hardened coconut oil. To assess bait uptake, bait markers can be incorporated in the bait matrix or the blister. During initial field trials, tetracycline was used ([@B41]). However, bait markers efficient in this species (i.e., tetracycline, iophenoxic acid, rhodamine) are supposed at risk for human health, since wild boar are hunted and consumed by people ([@B9]; [@B71]) and subsequently increase the overall cost of vaccination, which compromises the use of chemical markers at a large scale in natural populations ([@B25]; [@B6]). Beef tallow which was used in the original bait, was removed from the bait matrix because regulatory requirements limited the use of certain bait materials (e.g., products derived from terrestrial animals; tissues that may transmit spongiform encephalopathy). The bait has a relatively low melting point (30°C) and is therefore not suitable for distribution in areas during periods with high elevated temperatures. To protect the liquid vaccine against environmental factors, including the bait matrix, the formulated vaccine (1.6 ml) is filled in a vaccine container after vaccine production. Subsequently, the PVC vaccine container (20 mm × 20 mm × 7 mm) is sealed with an aluminum foil and incorporated into the bait matrix (40 mm × 40 mm × 15 mm). For CSFV it is important that the vaccine is released in the oral cavity so that it can be taken up by the tonsils to initiate the immune response. Therefore, to release the vaccine in the oral cavity of the wild boar, the animal needs to perforate the vaccine container with its teeth. If baits are too small, it could be swallowed without chewing and the vaccine blister will not be perforated. However, the present bait may be too big for piglets (\<4 months of age) to consume. [@B27] observed that piglets only played with the baits and showed an incomplete uptake. In this case, the vaccine was not released into the oral cavity, resulting in a failed vaccination attempt in juvenile wild boar. Also, shape and texture can influence bait handling and possibly result in increased vaccine spillage (e.g., dripping on the ground). Several baits composition and shapes were tested in piglets during a former European collaborative project but did not result in a better uptake in that age class in continental European countries. This may be due to the low palatability of baits in comparison with the natural food available during spring and summer when juvenile wild boars are still piglets ([@B72]; see An Adapted Bait Delivery Process). A field trial for wild boar vaccination in Italy with the new live marker vaccine "CP7_E2alf" and the classic IDT^®^ bait gave results similar to oral vaccination campaigns with C-strain which is encouraging for future vaccination applications even though the commercial version of the oral marker vaccine is not yet available ([@B28]).

Deployment Challenges
=====================

A Short History of Oral Mass Vaccination
----------------------------------------

There is always a big gap between the development of vaccination tools by researchers and the deployment of vaccination in the field ([@B82]). First, research results have to be translated into industrial products. Then, field trials are needed to assess the efficacy of the bait delivery process (see An Adapted Bait Delivery Process and Assessing Vaccination Efficacy) and allowing an official vaccine registration ([@B58]). After that, the process has to be adjusted to the specific local environmental conditions (An Adapted Bait Delivery Process). Regarding the C-strain, the only available oral vaccine currently available on the market, the industrial production and field trials were mainly implemented in Germany during the 1990's and early 2000's by [@B37], [@B41], [@B38], [@B43], [@B42], [@B44]) and the IDT^®^ company. Once the strategy is officially adopted, many practical problems must be solved before deployment including prerequisite and exhaustive census of the vaccination grounds, organizing the logistics for frozen or cold transportation and storage of several thousands of vaccine-baits within isolated areas, delivering the technical information to hunters and controlling bait distribution and consumption in the field. Stop-hunting 1 week before and during bait distributions has been implemented to avoid animal disturbance and to limit the risk of false PCR-positive results ([@B55]). Vaccine-baits alone are relatively cheap (around 1 euro per bait) so the cost of treating one square kilometer of forest averages 400--500 euro per year. However, significant secondary costs are associated with the management of endemically infected areas such as testing of hunter killed animals and incidentally discovered carcasses for CSF serology and virology, the compensation for carcass destruction (CSF positive carcasses to CSF virology are destroyed), the control of carcass identification and trade. During the 2000's in France the total cost of CSF management in wild boar was estimated around 1500 euro per square kilometer of treated forest and per year. Since the early 2000's, the use of OMV is officially supported by the European communities (Council Directive 2001/89/EC) and has been adopted in many countries as part of their emergency plan with an important proportion of success including Germany, Luxembourg, France, Slovakia, Bulgaria, and Latvia ([@B25]; [@B60]) (**Table [1](#T1){ref-type="table"}**). However, many challenges have to be still addressed for improving the baits delivery process, monitoring and efficacy (see further sections).

###### 

Documented classical swine fever (CSF) outbreaks in wild boar in Europe and management measures including oral mass vaccination (OMV).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Period          Country and region                     Reference                   Infected area (max)   Vaccinated area (max)      Outbreak period                                       Vaccination period   Restriction period    Vaccination treatment
  --------------- -------------------------------------- --------------------------- --------------------- -------------------------- ----------------------------------------------------- -------------------- --------------------- ------------------------------------
  1992--2002      Germany, Lower Saxony                  [@B41], [@B38]\             6278 km^2^            1300 km^2^ (1993--1994)\   12/1992\                                              10/1993\             12/1992\              Field trials\
                                                         FLI                                               5736 km^2^ (1997--2004)    13.06.2002                                            08/2004              12/2004               Two campaigns a year

  1999--2002      Germany, Saxony Anhalt                 FLI                         709 km^2^             3365 km^2^                 12.10.1999 19.09.2000                                 12/1999\             12.10.1999\           Field trials\
                                                                                                                                                                                            11/2001              31.12.2002            Two campaigns a year

  2001--2002      Germany, Saarland                      FLI                         275 km^2^             645 km^2^                  26.01.2001 13.06.2002                                 03/2002\             01/2001\              Field trials\
                                                                                                                                                                                            10/2003              06/2004               Two campaigns a year

  2002            Germany, Northrhine-Westphalia         EURL CSF-DB                 759 km^2^             1531 km^2^                 22.04.2002 14.10.2002                                 08/2002\             08/2002\              Field trials\
                                                                                                                                                                                            10/2004              09/2004               Two campaigns a year

  2005--2007      Germany, Northrhine-Westphalia         EURL CSF-DB                 1993 km^2^            1993 km^2^                 07.10.2005 04.05.2007                                 12/2005\             10/2005\              Three campaigns a year
                                                                                                                                                                                            03/2010              03/2010               

  1999--2002      Germany, M-W Pomerania                 [@B42]\                     12928 km^2^           13942 km^2^                01.03.1993 21.07.2000                                 12/1994\             01.03.1993\           Field trials\
                                                         FLI                                                                                                                                06/2002              31.12.2002            Two campaigns a year

  1995--1997      Germany, Brandenburg                   [@B45]\                     5059 km^2^            9173 km^2^                 14.03.1995 26.04.2000                                 04/1995\             14.03.1995\           Field trials\
                                                         FLI                                                                                                                                04/2001              31.12.2002            Two campaigns a year

  1999--2001      Germany, Baden-Württemberg             [@B49]\                     703 km^2^             1291 km^2^                 30.09.1998 19.11.1999                                 08/1999\             30.09.1998\           Three campaigns a year
                                                         FLI                                                                                                                                10/2001              31.12.2002            

  1997--2002      Italy,\                                [@B85]                      370 km^2^             None                       05/1997\                                              --                   05/1997\              No OMV\
                  Varese                                                                                                              12/2000                                                                    02/2002               limited collective hunting

  1985--1990      Italy, Tuscany South                   [@B69]\                     3800 km^2^            None                       10/1985\                                              --                   10/1985\              No OMV\
                                                         OIE                                                                          11/1990                                                                    11/1990               "Intensified" hunting

  1992--1995      Italy, Tuscany North                   [@B69]\                     304 km^2^             None                       01/04/1992\                                           --                   01/04/1992\           No OMV limited collective hunting
                                                         OIE                                                                          01/08/1992                                                                 12/1995               

  1995--1996      Italy,\                                [@B69]\                     75 km^2^              None                       09/1995\                                              --                   Not documented        No OMV\
                  Piacenza                               OIE                                                                          01/1996                                                                                          limited collective hunting

  1998--2000      Swiss, Ticino                          [@B74], OIE                 166 km^2^\            No vaccination done        05/1998\                                              --                   05/1998\              No OMV limited collective hunting
                                                                                     (risk area)                                      01/2000                                                                    01/2001\              
                                                                                                                                                                                                                 (OIE)                 

  1999--2003      Germany, Rhineland-Palatinate, Eifel   [@B83]\                     8568 km^2^            8600 km^2^                 05.01.1999 24.03.2003                                 02/2002\             01/1999\              Three vaccination campaigns a year
                                                         EURL CSF-DB                                                                                                                        03/2005              03/2008\              

  2002--2004      Germany\                               [@B83]\                     4833 km^2^            4300 km^2^                 23.10.1998 12.11.2004                                 01/2003\             06/2005\              Three vaccination campaigns a year
                  Rhineland-Palatinate, Palatinate       EURL CSF-DB                                                                                                                        02/2006              02/2008\              

  2009\           Germany, Right-Side of the Rhine       EURL CSF-DB                 5038 km^2^            5038 km^2^                 01/2009\                                              02/2009\             01/2009\              Three vaccination campaigns a year
                                                                                                                                      07/2009                                               04/2010              06/2012               

  2009            Germany,\                              EURL CSF-DB                 862 km^2^             862 km^2^                  02.03.2009\                                           03/2009\             02/2009\              Three vaccination campaigns a year
                  Rhineland-Palatinate,\                                                                                              30.04.2009                                            04/2010              06/2012               
                  Palatinate                                                                                                                                                                                                           

  1992--1997      France, Vosges du Nord                 [@B63],[@B64]                                     No OMV                     01/1992\                                              --                   01/1992\              No OMV\
                                                                                                                                      01/1997                                                                    12/2000               normal collective hunting

  2002--2003      Luxembourg, whole country              SANCO 10257/2003, [@B19]\   2592 km^2^            2592 km^2^                 11/2001\                                              03/2003\             11/2002\              Three vaccination campaigns a year
                                                         EURL CSF-DB                                                                  08/2002                                               09/2005              09/2005               

  2003            France Thionville                      [@B60]                      200 km^2^             No OMV                     04/2002\                                              --                   04/2003\              No OMV limited collective hunting
                                                                                                                                      07/2002                                                                    03/2005               

  2003--2007      France, Vosges du Nord                 [@B60]; [@B66]; [@B20]\     2890 km^2^            2890 km^2^ (1250)          14/04/2003\                                           08/2004\             09/2004\              Three vaccination campaigns a year
                                                         EURL CSF-DB                                                                  01/05/2007                                            06/2010              11/2011               

  2005--2008      Slovakia\                              EURL CSF-DB\                9897 km^2^            9897 km^2^                 07/2004\                                              02/2005\             07/2004\              Three vaccination campaigns a year
                                                         ADNS\                                                                        05/2008                                               11/2010              06/2011               
                                                         SCoFCAH                                                                                                                                                                       

  2004--2009      Bulgaria,\                             EURL CSF-DB\                35887 km^2^           35887 km^2^                05/2004\                                              07/2005\             05/2004\              Three vaccination campaigns a year
                                                         ADNS, WAHID\                                                                 09/2009                                               To date              To date               
                                                         SCoFCAH                                                                                                                                                                       

  2007--2009      Hungary                                ADNS\                       ∼4500 km^2^                                      01/2007\                                                                   01/2007\              No OMV
                                                         SCoFCAH                                                                      10/2009                                                                    09/2012               

  2006--2007      Romania                                ADNS\                       63247 km^2^           63247 km^2^                01/2006\                                              05/2007\             01/2006\              Three vaccination campaigns a year
                                                         SCoFCAH                                                                      11/2007                                               12/2011              09/2012               

  2002\           Belgium                                EURL CSF-DB\                743 km^2^             --                         11/2002\                                              --                   11/2002\              No OMV
                                                         ADNS                                                                         11/2002                                                                    01/2004               

  2012--to date   Latvia                                 ADNS\                       ∼9000 km^2^           ∼5000 km^2^                16.11.2012--to date (last reported case 26.03.2015)   05/2013--to date     16.11.2012--to date   Three vaccination campaigns a year
                                                         SCoFCAH                                                                                                                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FLI, Friedrich-Loeﬄer-Institut, Federal Research Institute for Animal Health, Germany; EURL CSF-DB, European database for Classical swine fever; OIE, world organization for animal health; SANCO, European Commission Directorate-General for Health and Consumers; ADNS, European Animal Disease Notification System; SCoFCAH, European Standing Committee on the Food Chain and Animal Health.

An Adapted Bait Delivery Process
--------------------------------

Currently, bait distribution is provided by hunters (i.e., by hand delivery) on feeding grounds. Attempts to distribute baits by aircraft were completed ([@B38]), but are not generally used, possibly due to high costs ([@B25]). Furthermore, several field studies confirmed that wild boar are omnivorous and opportunistic animals that need to be pre-baited before vaccine delivery in order to limit bait uptake by non-target species (e.g., red fox, badgers, martens, birds, etc; [@B72]; [@B9]). The C-strain vaccine bait has been classical delivered under ground to target wild boar specifically ([@B38]) and to protect live-vaccine against damage due to hot temperatures and consecutive efficacy loss. However, recent behavioral studies using camera traps and different delivery process demonstrated that baits put under ground may decrease wild boar uptake (especially in juvenile boar) while not effectively preventing the consumption by non-target species ([@B72]). Low bait uptake in piglets less than 6 months old has been a constant problem in previous vaccination attempts ([@B72]) and the consecutive low vaccination rates in that age class ([@B67]; [@B20]) have been a well know factor decreasing vaccination efficacy in both human and animal populations ([@B4]; see Retrospective Analyses based on Hunting Data). Interestingly, using specific feeders for excluding big animals did not improved the bait uptake in piglets ([@B70]) and small baits that were efficiently consumed by piglets in Spain ([@B8]) were poorly consumed in continental European areas, possibly as a result of different food availability between continental and Mediterranean ecosystems during summertime ([@B70], [@B72]). The current vaccination process is based on three double campaigns in spring, summer, and autumn; each campaign comprising two vaccine-baits-distribution spaced by 28 days, aiming at maximizing antibody titters (by booster vaccination) and the proportion of vaccinated juvenile wild boars ([@B42]; [@B25]). However, recent retrospective studies, taking into account wild boar demography and spatial structure, confirmed that bait uptake in juvenile wild boar less than 1 year is always very low in summer (∼5%) and autumn (\<30%) compared to spring (40--70%). This explains why 1 year is necessary for reaching a maximum seroprevalence in wild boar populations within these areas ([@B20]). The classic vaccination process corresponds to the delivery of about 40 baits per vaccination ground and a density of one to two vaccination ground per square kilometer of treated forest ([@B25]). The vaccination effort and the percentage of vaccinated wild boar are correlated until an optimum (i.e., 1.25 baiting places per km^2^ in North-eastern France) but vaccination efficacy is strongly influenced by the season and year in relation to natural food competing with feed stations and baits ([@B20]). Thus, it is probable that uncontrolled factors (i.e., temperature, rain fall, population dynamics, etc) generate huge variations in the vaccination success even though the baiting process is conserved or intensified from year to year. Finally, vaccination success relies on the delimitation of the vaccinated area, which we further discuss in Sections "Assessing Vaccination Efficacy and Alternative or Complementary Strategies."

Monitoring CSF within Vaccinated Areas
--------------------------------------

Monitoring CSF outbreaks when vaccinating with the C-strain vaccine has been challenging during the past deployment attempts, since the non-marker vaccine (C-strain) strongly impacts the performance and significance of the diagnostic tools. First, antibodies targeting the C-strain and the wild CSFV strains cannot be differentiated using serological tests ([@B12]; [@B23]; [@B15]). Therefore, during OMV, seroprevalence is indicative of an average level of population immunity but not of CSF circulation ([@B39]; [@B20]). Second, the proportion of viropositive individuals is very low in vaccinated populations, which compromises the probability of virus detection even though hunting bags are exhaustively examined within infected areas, (i.e., representing several thousands samples per year; [@B82]; [@B66]) using highly sensitive PCR tools ([@B17]). Additionally, among sparse PCR-positive results, false positive may occur after several vaccination campaigns, corresponding to C-train genome traces (in spleen samples), which interfere also with monitoring efficacy and justified the development of DIVA-PCR we yet described in Section "Diagnostic Tools" ([@B16]). After the completion of vaccination, seroprevalence remains high for some years, so that CSF circulation cannot be correctly monitored; surveillance has thus to be maintained for at least 3 years after OMV completion even though no more cases are detected ([@B39]; [@B65]; Saubusse et al., accepted). The longitudinal monitoring of capture-marked-recaptured wild boar may help in better interpreting wild boar immune response, but is also spatially limited and time consuming ([@B67]; Saubusse et al., accepted). The future development of a new marker vaccine would help to improve outbreak monitoring within vaccinated areas, since antibodies from vaccinated and infected animals could be differentiated using companion serological tests.

Assessing Vaccination Efficacy
==============================

Retrospective Analyses based on Hunting Data
--------------------------------------------

### At the Outbreak Level

Vaccination success was determined through retrospective studies based on field hunting data collected in Germany, Luxembourg, and France, which showed evidence of a significant increase of seroprevalence up to 60% and a quick decrease of viroprevalence under 1% within vaccinated areas within 1--6 years ([@B38], [@B43]; [@B83]; [@B66]). Nevertheless, vaccination success has not been complete as CSFV has been spreading in spite of vaccination in continuous forested areas ([@B38]) and CSFV may re-emerge after disappearance of the virus for several years ([@B25]). Such problems possibly arose because (i) vaccination areas were too small compared to the actual area at risk of disease spread (i.e., the whole connected forested areas), (ii) juvenile were not correctly immunized during the critical average age of infection, (iii) vaccination was not maintained for enough time ([@B25]). Retrospective analyses performed in France highlighted that, vaccination is not necessarily preventing CSF spread within connected forested areas, due to the fact emergency vaccination is not effective enough to break the chain of transmission immediately. Nevertheless, proactive vaccination, when performed within a 24 km width buffer vaccination area surrounding the virus wave front (i.e., corresponding to 1 year virus spreading average distance), is able to limit further disease persistence possibly by preventing the re-invasion between neighboring sub-populations ([@B66]). These results are logical since a maximum seroprevalence is ultimately reached after 1 year of deployment (i.e., after a complete cycle of three double vaccine distributions was achieved; [@B66]). An accurate delimitation of infected and vaccinated areas, according to landscape/forest structure and existing barriers, is thus considered as a critical step for controlling CSFV in wild boar using vaccination ([@B25]).

### At the European Level

As previously discussed by [@B63] and [@B50], the dimension of the risk areas (in square km^2^), which depends on forest extend and structure, has been the main factor influencing outbreaks duration from 1985 up to 2009 (*R*^2^ = 0.46, *p* \< 0.001, **Table [1](#T1){ref-type="table"}** and **Figure [1](#F1){ref-type="fig"}**), When OMV was performed three times a year, the average outbreaks duration decreased (OMV~effect~ = -13 months, ±10.8, *p* = 0.22), but at the same time, the average delay between the last viropositive result and the end of restrictions measures increased (OMV~effect~ = +12.9, ±5.1, *p* = 0.02); possibly as a result of the confusing effect of OMV on serological and PCR results (see Deployment Challenges). Thus, OMV has not reduced the cost of CSF management, but it has been the only strategy preventing outbreaks re-emergence in large connected forested areas in Europe \[e.g., Palatinate (Ge) and Vosges du Nord (Fr)\] ([@B25]; **Table [1](#T1){ref-type="table"}**).

![**Duration of outbreak (number of months with viropositive results) as a function of infected areas and of the vaccination treatment over 24 "fade out" outbreaks (1985 to 2009).** Green circles correspond to non-vaccinated areas, blue circles correspond to primary field trials using two simple or double campaigns a year (before 2002), pink circle correspond to the current oral mass vaccination (OMV) scheme using three double campaigns a year (mainly after 2002). The line is representing the average linear regression linking the duration of outbreak to infected areas.](fmicb-06-01141-g001){#F1}

Modeling Efficacy
-----------------

The epidemiological modeling of wildlife diseases is a tool used to support disease control and mitigation measures. Mathematical models from population ecology demonstrate the principle of OMV in wildlife ([@B3]). The approach focuses the estimation of a minimum population proportions that should be protected against infection during an OMV program to halt the spread of CSF. Along with early field trials of OMV such models proposed an average 40--50% population level immunity as sufficient to stop CSF spread ([@B35]; [@B34]). However, the models relied on critical simplifications that may have led to an underestimation of the threshold population immunity. The infectious period may differ between infected wild boar individuals because immunocompetency varies according to age and body condition, and the occurrence of rare chronic (i.e., long-lasting) infection is a critical factor regarding CSF dynamics ([@B50]) and vaccination efficacy ([@B52]), which could not be caught by average simplest models. Moreover, most of the wild boar populations subjected to OMV are big and distributed over large connected areal ([@B63]). Thus, the assumption of sufficiently contact within the complete population on the temporal scale of an individual CSF infection was not biologically reasonable and spatially explicit models were required for better understanding the persistence patterns of CSF in the wild. Next step to support OMV planning was the application of stochastic meta-population modeling that suggested a useful population level immunity of 60% ([@B25]) in line with field estimates from vaccination areas. More recent research, implementing individual-based models of wild-boars moving and getting infected in a spatially explicit habitat landscape, were finally implemented for testing different vaccination strategies ([@B52]). These last models highlighted that the probability of CSFV eradication particularly relied on the implementation of preventive vaccination and the maintenance of vaccination effort for at least 5 years ([@B52]). A possible next modeling step could be to take into account the temporal and spatial variation of vaccination efficacy ([@B20]).

Virus Evolution under Vaccination Pressure
------------------------------------------

Classical swine fever virus can be assigned to three genotypes with three to four sub-genotypes each. These genotypes do not translate into serotypes that pose a problem in diagnostics or vaccination. Over the last decade, mainly strains of genotype 2, especially 2.1 and 2.3 were circulating in Europe. In the wild boar, only subtype 2.3 was prevalent (for review see [@B11]). In general, CSFV is exceptionally stable for an RNA virus ([@B81]), and mass application of the C-strain did not induce a detectable evolution of the virus in the wild (see below). Indeed, due to this observed genetic stability, even a single point mutation could be considered relevant for molecular epidemiological studies of CSF outbreaks. The evidence of separate evolution of the two outbreaks in the 1990--2000's traced one outbreak to the strain Rostock and the other to the strain Uelzen in France and Germany. This has shown that environmental factors including absence of a forest continuum between two regions have a real contribution to containment of the disease ([@B60]; [@B78]). More recently, full genome sequencing has been carried out to investigate the evolution of the CSFV during a long-term outbreak within the wild boar population in the Vosges du Nord mountains region. The samples were chosen based on the results of partial sequencing ([@B78]) and the availability of temporal and spatial data in relation to the application of the C strain vaccine. It was demonstrated that the identified clusters were associated with the presence of barriers including roads, rivers, or railways rather than to a viral strategy to escape to the vaccine immune response.

Alternative or Complementary Strategies
=======================================

What about the Depopulation Option?
-----------------------------------

During the 1980's and early 1990's, the "pre-vaccination era," wild boar density was considered to be the main factor favoring virus emergence and endemic persistence; reaching a threshold value of about 1 wild boar per km^2^ was recommended for achieving virus eradication according to a pure density-dependent argument and assuming a high virulence of virus strains ([@B35]; [@B34]). At that time, CSF control in wild boar was supposed to be achieved through depopulation only, such as used in domestic pigs, and depopulation was expected to be performed by increasing hunting pressure and/or destroying trap-captured animals ([@B25]). Such depopulation strategy was even recommended by the European experts and the former EU legislation to the member states faced with CSF in wild boar ([@B2]; 91/685/CEE, Art. 6, par. 5, letter e). In practice, the depopulation strategy has never been satisfactory for controlling outbreaks in wild populations, and was even considered as an aggravating factor for CSF spread and persistence by some authors ([@B51]; [@B7]; [@B74]). Many reasons could explain the failure of the depopulation strategy, even if the density-dependent approach had been effective, including (i) wild boar density at which the virus could fade out was probably lower than that which could be achieved through hunting, (ii) the exact population size and density of the involved wild boar population were rarely known, and (iii) the low acceptability of depopulation among hunters, especially when targeting females and very young piglets ([@B25]). In the field, it is likely that the infected populations were managed according to typical hunting strategies, focused on maintaining or increasing a populations' size, with moderate hunting pressure on reproducing females ([@B30]; [@B46]). One may even fear that the actual hunting pressure during the early stage of the outbreaks was actually lower than before CSFV emergence due to the lethality induced by the virus and the difficulty of hunting sparse animals ([@B63]). Additional "depopulation tools" such as trap-capture or poisoning, were sometimes carried out in the field in Europe ([@B2]), but trapping is not cost-effective for the large-scale management of wild boar and poisoning has been considered unacceptable for both animal welfare and human safety in Europe ([@B25]). Finally, more recent studies suggested that the density-dependent approach was not effective for eradication of CSF given that: (i) wild boar density is not the main factor driving CSF persistence which rather relys on landscape structure (related to the total population size at risk) and the moderate virulence of virus strains involved in wild outbreaks ([@B63]; [@B50]), (ii) increasing hunting pressure might increase population turnover and increase the risk of disease persistence in naïve piglets ([@B25]), (iii) hunting is known to increase home range size and could thus contribute to increasing the mixing and disease transmission between social groups or subpopulations ([@B47]; [@B73]). It is notable that the depopulation strategy was again addressed by the European communities regarding the management of African Swine Fever (ASF) recently emerging in the European wild boar; depopulation was not considered as an suitable option given its lack of efficacy, in spite of a lack of available vaccine ([@B26]; [@B31]).

Restraining Wild Boar Movements and CSF Spread
----------------------------------------------

The intrinsic spreading of CSF within natural wild boar populations relies mainly on the forest structure and the presence of physical barriers. Due to the forest habitat of the species, the main factor influencing CSF spread (and persistence) within wild boar populations is the connectivity (∼distance) between neighbor forest patches ([@B63], [@B66]). Physical barriers may also participate in limiting animal movements, especially fenced motorways and major rivers or lakes ([@B51]; [@B74]; [@B66]). However, the efficacy of barriers for preventing animal movements depends on their nature and/or the combination with the forest structure ([@B57]). The reliability and practicability of erecting fences for preventing disease spread in wild boar has been addressed regarding both CSF and ASF control in Europe ([@B25], [@B26]). In theory, this solution is attractive especially when OMV is not possible, but in practice it has been found poorly satisfactory (e.g., the recent spread of ASF in Lithuania in spite of huge fencing efforts, [@B26]). The main problems with using fences include that: (i) it is costly, (ii) it takes time to build during which diseases may spread further, (iii) our knowledge about the exact position of the wave front of a wildlife disease at time t is not always accurate, (iv) wild boar are very good at damaging fences and fences must be regularly checked and fixed, which is costly and seldom achieved. As discussed previously, collective hunting is expected to increase animal home range and dispersal, thus hunting bans or banning of hunting dogs during collective hunting has been implemented around physical barriers to limit the risk disease spread out of infected areas ([@B55]; [@B67]). Nevertheless, hunting restrictions do not prevent natural seasonal movements of wild boars, which are often unrelated to human activities ([@B77]). Finally, a main aspect for control of CSF spread in wild boar is the prevention of direct and indirect contacts between wild boar and domestic pigs, which relies essentially on (i) biosecurity measures and swill feeding control at pig farms (ii) control of wild boar feeding, carcass trade and viscera releases ([@B51]; [@B25]).

Conclusion
==========

Wild boar vaccination against CSF has been applied for more than 15 years in the EU using a highly efficient live attenuated vaccine, the C strain-Riems, delivered in baits. While intensifying hunting or erecting fences has not been adequate for preventing disease spread or persistence, OMV has proved to be effective in maintaining herd immunity and achieving CSF control; it is the only available method for CSF eradication in large forested areas. On the other hand, CSF may also be quickly eradicated without vaccination in small forested areas (\<1000 km^2^) well delimited by physical barriers by establishing hunting restrictions to avoid disease spread (e.g., Thionville in France and Ticino in Switzerland). Obviously, CSF control is also dependant on the precautionary measures taken for carcasses control and pig farm biosecurity. An integrated strategy is preferred to a single one to maximize the chance of success and also combining other strategies with vaccination should be considered. It is interesting to note that intensified hunting, feeding bans and fencing were recently re-evaluated as possible management measures for controlling ASF in Europe and were not considered to be adequate since now, given past experience during CSF outbreaks ([@B25], [@B26]).

The current OMV method relies on multiple bait distributions per year which represents a huge collective effort. Thus, it relies on the involvement of the stakeholders including hunters, wildlife agencies, local, and central veterinary services, and local and reference laboratories. Efforts must be coordinated between neighboring regions or countries when sharing the same forested areas, wild boar populations and outbreaks. Management success relies not only on baiting intensity or the number of vaccination campaigns. First, the landscape structure (forest and barriers) has to be considered for determination of the infected areas and development of a monitoring scheme. This enables quick and proactive deployment of OMV (24 km buffer area). Second, a multiple-year application of OMV is necessary to prevent CSF re-emergence. Furthermore, OMV does not generate genetic evolution of the virus strains.

Oral mass vaccination is costly during and after OMV deployment; carcass monitoring and restrictions last for several years after vaccination due to the confounding effect of non-marker vaccine on surveillance hunting data. Diagnostic tools have to be reliable and adapted for this purpose. Future outbreaks could be addressed and controlled more rapidly using oral marker vaccine (which is validated but not yet commercially available) and companion serological tools (which have to be validated). Even if the youngest piglets cannot eat the baits, experience of the last years of vaccination showed that they were protected by maternally derived antibodies. Therefore, applying repeated vaccination for adult females could avoid this possible failure in vaccination programs.
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